231 results on '"Imatinib therapy"'
Search Results
2. Patent Issued for Methods of treating gastrointestinal stromal tumors (USPTO 12059411).
- Subjects
GASTROINTESTINAL stromal tumors ,INVENTORS ,DIGESTIVE system diseases ,SOFT tissue tumors ,PROTEIN kinase inhibitors ,C-kit protein - Abstract
The article focuses on the issuance of a patent to Deciphera Pharmaceuticals for new methods of treating gastrointestinal stromal tumors (GIST). Topics include the prevalence and genetic mutations associated with GIST, the evolution of targeted therapies such as imatinib, and the challenges posed by drug resistance due to secondary mutations.
- Published
- 2024
3. Patent Issued for Method of administering Lapatinib to a canine to treat bladder cancer harboring a BRAF mutation (USPTO 12036281).
- Published
- 2024
4. Patent Issued for Methods of treating gastrointestinal stromal tumors (USPTO 12023326).
- Subjects
GASTROINTESTINAL stromal tumors ,INVENTORS ,SOFT tissue tumors ,DIGESTIVE system diseases ,PROTEIN kinase inhibitors ,C-kit protein - Abstract
A patent has been issued for methods of treating gastrointestinal stromal tumors (GIST) by administering ripretinib or a pharmaceutically acceptable salt thereof. GISTs are rare tumors that occur in the gastrointestinal tract, with mutations in KIT and PDGFRA genes being common. Imatinib is a commonly used treatment, but resistance can develop. The patent describes various dosing regimens for ripretinib in patients whose tumors have progressed or who are intolerant to imatinib. The methods aim to provide effective treatment options for GIST patients. [Extracted from the article]
- Published
- 2024
5. Patent Issued for Methods of treating gastrointestinal stromal tumors (USPTO 12023327).
- Subjects
GASTROINTESTINAL stromal tumors ,INVENTORS ,SOFT tissue tumors ,DIGESTIVE system diseases ,PROTEIN kinase inhibitors ,C-kit protein - Abstract
A patent has been issued to Deciphera Pharmaceuticals LLC for methods of treating gastrointestinal stromal tumors (GIST). GISTs are rare tumors that occur in the gastrointestinal tract, with the majority of cases caused by mutations in the KIT or PDGFRA genes. The patent describes the use of ripretinib, a tyrosine kinase inhibitor, as a potential treatment for advanced GIST in patients who have progressed from or are intolerant to previous therapies such as imatinib. The patent outlines various dosing regimens for ripretinib and claims that the treatment can provide about 15 months of survival in patients who have received at least 4 lines of prior therapy. [Extracted from the article]
- Published
- 2024
6. Patent Issued for Methods of treating gastrointestinal stromal tumors (USPTO 12023325).
- Subjects
GASTROINTESTINAL stromal tumors ,INVENTORS ,SOFT tissue tumors ,DIGESTIVE system diseases ,PROTEIN kinase inhibitors ,C-kit protein - Abstract
A patent has been issued to Deciphera Pharmaceuticals LLC for methods of treating gastrointestinal stromal tumors (GIST). GISTs are rare tumors that occur in the gastrointestinal tract, with the majority of cases caused by mutations in the KIT or PDGFRA genes. The patent describes a method of treating advanced GIST by administering ripretinib, a tyrosine kinase inhibitor, to patients who have previously been treated with imatinib. The treatment aims to provide more than 3 months of progression-free survival in patients. The patent also includes various dosage regimens for ripretinib administration. [Extracted from the article]
- Published
- 2024
7. Patent Issued for Combination therapy with liposomal antisense oligonucleotides (USPTO 12012601).
- Subjects
OLIGONUCLEOTIDES ,PROTEIN-tyrosine kinase inhibitors ,PROTEIN kinase inhibitors ,PHILADELPHIA chromosome ,CHRONIC myeloid leukemia ,SKIN cancer - Abstract
A patent has been issued for a combination therapy involving liposomal antisense oligonucleotides for the treatment of cancer. The therapy targets the Grb2 nucleic acid and utilizes a Bcr-Abl tyrosine kinase inhibitor. The patent describes the background of chronic myelogenous leukemia (CML) and the genetic rearrangement that leads to the activation of the RAS and PI3K pathways. The invention aims to provide more effective treatments for CML patients who are in accelerated or blast phase or who are resistant to tyrosine kinase inhibitors. The patent includes methods of administration and dosage recommendations for the therapy. [Extracted from the article]
- Published
- 2024
8. Patent Issued for Combination therapy for the treatment of gastrointestinal stromal tumor (USPTO 11986463).
- Abstract
A patent has been issued for a combination therapy for the treatment of gastrointestinal stromal tumor (GIST). The therapy involves the use of a c-KIT inhibitor in combination with an inhibitor of the MAPKAP kinase signaling pathway. The combination has been shown to lead to cell death, apoptosis, and prolonged cell stasis of GIST cells, as well as enhanced tumor regression in vivo. The therapy is particularly effective for GIST patients who are resistant to imatinib treatment. [Extracted from the article]
- Published
- 2024
9. Patent Issued for Inhaled imatinib for treatment of pulmonary arterial hypertension (PAH) (USPTO 11980689).
- Subjects
PULMONARY arterial hypertension ,IMATINIB ,SALTWATER solutions ,FLUTICASONE propionate - Abstract
Avalyn Pharma Inc. has been issued a patent for inhaled imatinib, a phenylaminopyrimidine derivative and kinase inhibitor compound, for the treatment of various fibrotic diseases, cancers, and hypertensive diseases. The patent describes compositions and methods for delivering imatinib through inhalation to improve efficacy and reduce patient resistance. The invention includes an aqueous solution for nebulized inhalation administration, which may contain tyrosine kinase inhibitors, inorganic salts, buffers, and other ingredients. The patent also outlines a method for treating pulmonary arterial hypertension by administering aerosolized imatinib in a specific dose range. [Extracted from the article]
- Published
- 2024
10. Study Results from Hamad Medical Corporation Broaden Understanding of Chronic Myeloid Leukemia (The Applicability of Tyrosine Kinase Inhibitors in Pediatric Chronic Myeloid Leukemia).
- Subjects
CHRONIC myeloid leukemia ,PROTEIN-tyrosine kinase inhibitors ,PROTEIN kinase inhibitors ,MYELOID leukemia ,PEDIATRIC therapy - Abstract
A recent study conducted by the Hamad Medical Corporation explored the use of tyrosine kinase inhibitors (TKIs) in the treatment of pediatric chronic myeloid leukemia (CML). The study analyzed 17 randomized controlled trials involving 887 pediatric CML patients. The results showed that TKIs, particularly imatinib, were effective in treating pediatric CML with response rates ranging from 60% to 78% and complete cytogenetic response rates ranging from 62% to 94%. However, there were concerns regarding the reporting of efficacy data in the trials. The study also highlighted the safety profile of TKIs, which was consistent with that observed in adults. The researchers emphasized the need for more prospective clinical trials and real-life clinical practice to establish appropriate guidelines for the treatment of pediatric CML with TKIs. [Extracted from the article]
- Published
- 2023
11. Patent Issued for Methods of treating gastrointestinal stromal tumors (USPTO 11813251).
- Subjects
GASTROINTESTINAL stromal tumors ,MEDICAL personnel ,PROTEIN-tyrosine kinase inhibitors ,C-kit protein ,PATENTS ,GENETIC counseling - Abstract
A patent has been issued to Deciphera Pharmaceuticals LLC for methods of treating gastrointestinal stromal tumors (GIST). GISTs are rare tumors that occur in the gastrointestinal tract, with the majority of cases caused by mutations in the KIT or PDGFRA genes. The patent describes a method of treating advanced GIST by administering ripretinib, a tyrosine kinase inhibitor, to patients who have previously been treated with imatinib. The treatment aims to provide more than 6 months of progression-free survival in patients. This patent provides valuable information for researchers and healthcare professionals studying and treating GIST. [Extracted from the article]
- Published
- 2023
12. Investigators from Cold Spring Harbor Laboratory Target Xenografts (Patient-derived Xenografts and In Vitro Model Show Rationale for Imatinib Mesylate Repurposing In Hey1-ncoa2-driven Mesenchymal Chondrosarcoma).
- Abstract
Cold Spring Harbor, State:New York, United States, North and Central America, Antineoplastics, BCR-ABL Tyrosine Kinase Inhibitors, Biotechnology, Business, Cancer, Chondrosarcoma, Cold Spring Harbor Laboratory, Drugs and Therapies, Health and Medicine, Imatinib Therapy, Oncology, Pharmaceuticals, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors, Xenografts, Xenotransplantion Keywords: Cold Spring Harbor; State:New York; United States; North and Central America; Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Biotechnology; Business; Cancer; Chondrosarcoma; Cold Spring Harbor Laboratory; Drugs and Therapies; Health and Medicine; Imatinib Therapy; Oncology; Pharmaceuticals; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; Xenografts; Xenotransplantion EN Cold Spring Harbor State:New York United States North and Central America Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Biotechnology Business Cancer Chondrosarcoma Cold Spring Harbor Laboratory Drugs and Therapies Health and Medicine Imatinib Therapy Oncology Pharmaceuticals Protein Kinase Inhibitors Tyrosine Kinase Inhibitors Xenografts Xenotransplantion 1213 1213 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Biotechnology - Xenografts. [Extracted from the article]
- Published
- 2023
13. Therapeutic drug monitoring in oncology
- Author
-
Etienne Chatelut, Richard A. Larson, Jennifer H. Martin, William Clarke, Salvatore J. Salamone, Ron H.J. Mathijssen, and Alan Kambiz Fotoohi
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Consensus ,Oral chemotherapy ,Imatinib therapy ,Clinical toxicology ,Medical Oncology ,Toxicology ,SDG 3 - Good Health and Well-being ,Neoplasms ,Internal medicine ,medicine ,Humans ,Voluntary Health Agencies ,Dosing ,Protein Kinase Inhibitors ,Dose-Response Relationship, Drug ,medicine.diagnostic_test ,business.industry ,Imatinib ,Therapeutic drug monitoring ,Practice Guidelines as Topic ,Imatinib Mesylate ,Drug dosing ,Drug Monitoring ,business ,medicine.drug - Abstract
Although therapeutic drug monitoring (TDM) is an important tool in guiding drug dosing for other areas of medicine including infectious diseases, cardiology, psychiatry and transplant medicine, it has not gained wide acceptance in oncology. For imatinib and other tyrosine kinase inhibitors, a flat dosing approach is utilised for management of oral chemotherapy. There are many published studies examining the correlation of blood concentrations with clinical effects of imatinib. The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) determined that there was a need to examine the published literature regarding utility of TDM in imatinib therapy and to develop consensus guidelines for TDM based on the available data. This article summarises the scientific evidence regarding TDM of imatinib, as well as the consensus guidelines developed by the IATDMCT.
- Published
- 2021
14. Patent Issued for Pharmaceutical formulations of imatinib and uses thereof (USPTO 11752152).
- Abstract
The following quote was obtained by the news editors from the background information supplied by the inventors: "Imatinib is a potent small molecule tyrosine-protein kinase inhibitor originally developed for the treatment of chronic myelogenous leukemia (CML). Keywords: Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Business; COVID-19; Coronavirus; Critical Care Medicine; Drugs and Therapies; Epidemiology; Exvastat Ltd.; Glycerol; Health and Medicine; Hospitals; Imatinib Therapy; Intensive Care Medicine; Mortality; Pharmaceuticals; Protein Kinase Inhibitors; RNA Viruses; SARS-CoV-2; Severe Acute Respiratory Syndrome Coronavirus 2; Sugar Alcohols; Tyrosine Kinase Inhibitors; Viral; Virology EN Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Business COVID-19 Coronavirus Critical Care Medicine Drugs and Therapies Epidemiology Exvastat Ltd. Glycerol Health and Medicine Hospitals Imatinib Therapy Intensive Care Medicine Mortality Pharmaceuticals Protein Kinase Inhibitors RNA Viruses SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 Sugar Alcohols Tyrosine Kinase Inhibitors Viral Virology 3530 3530 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- A patent by the inventors Cavalla, David (Huntingdon, GB), Purdy, Keith (Huntingdon, GB), filed on June 27, 2022, was published online on September 12, 2023, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Antineoplastics, BCR-ABL Tyrosine Kinase Inhibitors, Business, COVID-19, Coronavirus, Critical Care Medicine, Drugs and Therapies, Epidemiology, Exvastat Ltd., Glycerol, Health and Medicine, Hospitals, Imatinib Therapy, Intensive Care Medicine, Mortality, Pharmaceuticals, Protein Kinase Inhibitors, RNA Viruses, SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2, Sugar Alcohols, Tyrosine Kinase Inhibitors, Viral, Virology. [Extracted from the article]
- Published
- 2023
15. Evaluation of the Relationship Between Initial Lymphocyte Count and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukaemia Patients
- Author
-
Elif Suyanı, Vahit Can Çavdar, Mehmet Hilmi Dogu, and Istemi Serin
- Subjects
Oncology ,optimal ,medicine.medical_specialty ,warning ,business.industry ,Lymphocyte ,lcsh:R ,lcsh:Medicine ,molecular response ,Imatinib therapy ,lymphocyte ,Chronic myeloid leukaemia ,failure ,medicine.anatomical_structure ,imatinib ,hemic and lymphatic diseases ,Internal medicine ,Molecular Response ,medicine ,business ,neoplasms - Abstract
Introduction:Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm characterised by the overproduction of haematopoietic cells in the granulocytic series, involving translocation of chromosomes 9 and 22. The first tyrosine kinase inhibitor, imatinib, used in the treatment of CML, represents one of the most successful targeted therapies marking a new era in the treatment of CML. Many scoring systems such as the Hasford and Sokal systems have been developed to stratify CML patients into risk categories, and to predict patient outcome. We aimed to evaluate the relationship between blood lymphocyte count (BLC) at diagnosis and molecular response to imatinib therapy as a prognostic factor.Methods:A total of 108 chronic phase CML patients diagnosed between January 2010 and January 2020 were evaluated. Patient characteristics, laboratory results, BLC and response to treatment were recorded.Results:The median BLC was 4,665/mm3 and patients were divided into two groups according to the median BLC as ≤4,665/mm³ and >4,665/mm³. The responses at 3, 6, 12 month and the final status of patients, namely achievement of major molecular response or not, did not differ between the two groups of patients.Conclusion:The introduction of new therapeutic options in CML necessitates improvement in existing risk scoring systems. No direct relationship was found between the initial BLC and imatinib response in CML. However this is the first study exploring the role of BLC at diagnosis in CML patients receiving imatinib, and further studies that look into lymphocyte subgroups as well as bone marrow lymphocyte count at diagnosis might allow a more precise evaluation about the contribution of lymphocyte count to risk assessment in CML patients.
- Published
- 2020
16. Pregnancy Outcome in Chronic Myeloid Leukemia on Imatinib Therapy - A Report of Three Patients
- Author
-
Geethu Babu, Manisha Verma, Shruthi Prem, and Biju Azariah
- Subjects
Oncology ,medicine.medical_specialty ,Pregnancy ,business.industry ,Internal medicine ,medicine ,Myeloid leukemia ,General Medicine ,Imatinib therapy ,medicine.disease ,business ,Outcome (game theory) - Published
- 2020
17. Acute myeloid leukemia with t(11;19)(q23;p13.1) in a patient with a gastrointestinal stromal tumor undergoing imatinib therapy: A case report
- Author
-
Jae Joon Han, Sun Kyung Baek, Chi Hoon Maeng, Si-Young Kim, Tae Sung Park, and Hong Jun Kim
- Subjects
congenital, hereditary, and neonatal diseases and abnormalities ,biology ,business.industry ,Myeloid leukemia ,Case Report ,Imatinib ,General Medicine ,Imatinib therapy ,03 medical and health sciences ,0302 clinical medicine ,KMT2A ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,Medicine ,030211 gastroenterology & hepatology ,Stromal tumor ,business ,neoplasms ,medicine.drug - Abstract
BACKGROUND: Acute myeloid leukemia (AML) harboring 11q23 translocations is classified as therapy-related AML in patients who have undergone prior treatment with cytotoxic agents. There have been only a few reports of AML that subsequently developed during imatinib mesylate (IM) treatment for gastrointestinal stromal tumors (GISTs). CASE SUMMARY: A 63-year-old woman was diagnosed with a hepatic GIST recurrence in April 2012; she was administered IM 400 mg/d. In November 2015, she developed dyspnea with pancytopenia while IM treatment was continued for 42 mo. A chromosome study using a bone marrow sample showed a 46, XX karyotype with t(11;19)(q23;p13.1) in 22 of 26 analyzed metaphase cells. Fluorescence in situ hybridization using the locus-specific indicator (11q23) gene break-apart probe showed positive rearrangement in 82% of interphase cells. Reverse-transcription polymerase chain reactions subsequently confirmed the KMT2A/ELL transcript. She achieved complete response with incomplete neutrophil recovery with two decitabine treatment cycles. After the third cycle of decitabine, the disease relapsed, and she refused further treatment. She died of hemorrhagic stroke 5 mo after diagnosis. To the best of our knowledge, this is the first report of AML with KMT2A gene rearrangements in a patient with a GIST receiving IM treatment. CONCLUSION: Physicians should consider the potential risks of developing hematologic malignancies, including therapy-related AML, in patients with GISTs receiving IM treatment.
- Published
- 2020
18. Adjunct Treatment of Recalcitrant Hand Plaques in Nephrogenic Systemic Fibrosis After Imatinib Therapy
- Author
-
Michael Rivlin, James P. Foshee, Thomas D. Griffin, Kristin Cam, and Matthew C. Keller
- Subjects
medicine.medical_specialty ,business.industry ,Skin thickening ,Imatinib ,Imatinib therapy ,medicine.disease ,Trunk ,Adjunct ,Surgery ,Imatinib mesylate ,Nephrogenic systemic fibrosis ,Medicine ,Joint Contracture ,business ,medicine.drug - Abstract
Nephrogenic systemic fibrosis (NSF) is a sclerotic disorder presenting with painful indurated plaques and skin thickening involving the trunk and extremities, which can lead to tethering and joint contractures. NSF most commonly affects patients with renal insufficiency who have been exposed to gadolinium. We present a case of NSF involving the bilateral hands, knees, and lower extremities developing over 10 years after gadolinium exposure. Initial improvement was noted in the lower extremities after initiation of imatinib mesylate therapy, but recalcitrant, thickened hand plaques caused persistent pain and functional limitation. Adjunct intralesional corticosteroid injections produced durable softening of the recalcitrant lesions with considerable functional improvement in hand mobility. Based on our experience, intralesional corticosteroid injections appear to be an effective adjunct treatment in patients with incomplete response to anti-fibrotic therapies.
- Published
- 2019
19. Certara UK Ltd. Researcher Adds New Study Findings to Research in Cancer (Physiologically Based Pharmacokinetic Modelling to Predict Imatinib Exposures in Cancer Patients with Renal Dysfunction: A Case Study).
- Subjects
IMATINIB ,KIDNEY diseases ,RENAL cancer ,PHARMACOKINETICS ,CANCER patients - Abstract
Keywords: Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Business; Cancer; Drugs and Therapies; Health and Medicine; Imatinib Therapy; Kidney; Nephrology; Oncology; Pharmaceutical Services Companies; Pharmaceuticals; Pharmacokinetics; Pharmacology; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors EN Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Business Cancer Drugs and Therapies Health and Medicine Imatinib Therapy Kidney Nephrology Oncology Pharmaceutical Services Companies Pharmaceuticals Pharmacokinetics Pharmacology Protein Kinase Inhibitors Tyrosine Kinase Inhibitors 164 164 1 07/31/23 20230731 NES 230731 2023 AUG 1 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on cancer is the subject of a new report. Antineoplastics, BCR-ABL Tyrosine Kinase Inhibitors, Business, Cancer, Drugs and Therapies, Health and Medicine, Imatinib Therapy, Kidney, Nephrology, Oncology, Pharmaceutical Services Companies, Pharmaceuticals, Pharmacokinetics, Pharmacology, Protein Kinase Inhibitors, Tyrosine Kinase Inhibitors. [Extracted from the article]
- Published
- 2023
20. Bone Health in Patients of Chronic Myeloid Leukemia on Imatinib Therapy
- Author
-
Munmun Yadav and Ajay Yadav
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Myeloid leukemia ,In patient ,General Medicine ,Imatinib therapy ,business ,Bone health - Published
- 2021
21. Researchers from Gossamer Bio Inc. Detail New Studies and Findings in the Area of Hypertension (Inhaled Seralutinib Exhibits Potent Efficacy In Models of Pulmonary Arterial Hypertension).
- Abstract
We examined the preclinical efficacy of inhaled seralutinib, a unique small-molecule PDGFR/CSF1R/c-KIT kinase inhibitor in clinical development for PAH, in comparison to a proof-of-concept kinase inhibitor, imatinib. Keywords: San Diego; State:California; United States; North and Central America; Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Business; Cardiovascular Diseases and Conditions; Drugs and Therapies; Enzymes and Coenzymes; Health and Medicine; Hypertension; Imatinib Therapy; Kinase; Pharmaceuticals; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors EN San Diego State:California United States North and Central America Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Business Cardiovascular Diseases and Conditions Drugs and Therapies Enzymes and Coenzymes Health and Medicine Hypertension Imatinib Therapy Kinase Pharmaceuticals Protein Kinase Inhibitors Tyrosine Kinase Inhibitors 800 800 1 03/23/23 20230310 NES 230310 2023 MAR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Cardiovascular Diseases and Conditions - Hypertension have been published. [Extracted from the article]
- Published
- 2023
22. Patent Issued for Methods of treating gastrointestinal stromal tumors (USPTO 11576904).
- Subjects
GASTROINTESTINAL stromal tumors ,INVENTORS ,SOFT tissue tumors ,DIGESTIVE system diseases ,PROTEIN kinase inhibitors ,C-kit protein - Abstract
"In another embodiment, described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg to 600 mg, e.g., 100 mg to 250 mg, e.g., 150 mg, of ripretinib daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib. "For example, in one embodiment described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg to 250 mg, e.g., 150 mg, of ripretinib daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib. "For example, in one embodiment described herein is a method of treating a patient suffering from an advanced gastrointestinal stromal tumor, comprising orally administering to the patient 100 mg to 300 mg, e.g., 150 mg, of ripretinib daily, wherein the patient's tumor has progressed from, or the patient was intolerant to, a previous first line administration of imatinib. [Extracted from the article]
- Published
- 2023
23. Neoadjuvant Imatinib Therapy Followed by Surgery in a Rare Case of Rectal Gastrointestinal Stromal Tumor
- Author
-
Nishant Malviya
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Rare case ,medicine ,Imatinib therapy ,Stromal tumor ,business - Published
- 2020
24. Isolated central nervous system blast crisis in chronic myeloid leukemia - Report of two cases
- Author
-
Jhansi Rani Arumugam, Jayachandran Perumal Kalaiyarasi, B K Karthik Bommannan, and Shirley Sundersingh
- Subjects
Blast Crisis ,business.industry ,Central nervous system ,Myeloid leukemia ,Imatinib ,Imatinib therapy ,Cns penetration ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Pediatrics, Perinatology and Child Health ,Cancer research ,Medicine ,In patient ,business ,neoplasms ,030215 immunology ,medicine.drug - Abstract
Extramedullary blast crisis (BC) presenting as the central nervous system (CNS) involvement in chronic myeloid leukemia (CML) is rare and usually accompanies systemic involvement. Imatinib has shown efficacy in treating patients with CML in accelerated or blastic phases. However, CNS penetration of Imatinib is poor due to the P-glycoprotein mediated efflux mechanisms. Therefore, patients on long-term Imatinib therapy with hematological and cytogenetic remission may rarely present with CNS BC. Isolated CNS BC is uncommon and the literature is limited to only a few case reports. Here, we present two cases of isolated CNS BC in patients with BCR ABL positive CML on treatment.
- Published
- 2020
25. Decoding a mysterious morphology with molecular pathology: chondroid metaplasia in a metastatic gastrointestinal stromal tumour after imatinib therapy
- Author
-
Jeremy N. Pulvers, Alexander Guminski, Mahsa Ahadi, Anthony J. Gill, and Angela Chou
- Subjects
Pathology ,medicine.medical_specialty ,Stromal cell ,Molecular pathology ,business.industry ,medicine ,Morphology (biology) ,Imatinib therapy ,business ,Chondroid metaplasia ,Pathology and Forensic Medicine - Published
- 2020
26. Melasma-like pigmentation during imatinib therapy for chronic myeloid leukemia
- Author
-
Jayesh Mukhi, Mugdha Manoj Kulkarni, S. M. S. Tomar, Rajesh P Singh, and Bhagyashree B Supekar
- Subjects
medicine.medical_specialty ,Melasma ,business.industry ,medicine ,lcsh:Dermatology ,Myeloid leukemia ,Imatinib therapy ,lcsh:RL1-803 ,medicine.disease ,business ,Dermatology - Published
- 2020
27. Effectivity of imatinib therapy for the management of chronic myeloid leukemia patients
- Author
-
Mollah Obayedullah Baki, Mokter Hossain, Tamanna E Nur, and Zannatul Ferdous Jesmin
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,hemic and lymphatic diseases ,Applied Mathematics ,General Mathematics ,Internal medicine ,medicine ,Myeloid leukemia ,Imatinib therapy ,business - Abstract
Background: First generation tyrosine kinase inhibitor, imatinib revolutionized the treatment of chronic myeloid leukaemia, and is now the front line therapy. Imatinib provides substantial cytogenetic and molecular remission, with minimal normal hematopoiesis suppression or side effects and is now first line therapy. Objective: The aim of this prospective study was to determine the efficacy of imatinib therapy in the management of chronic myeloid leukemia in Bangladesh. Methods: This prospective study was done from June 2012 to May 2018. In this period we treated eight chronic myeloid leukaemia patients with imatinib, in Khulna division, Bangladesh. Results: Majority of the patients (50%) were in the age group of 21-30 years. Three patients died as because those patients were too poor to continue drugs. Another 5 patients were in good health and continuing follow up monthly. Among five patients, one patient have two healthy son. Conclusion: Imatinib therapy is an effective treatment regimen in the management of chronic myeloid leukaemia. The best result can be obtained if CML is dignosed earlier. Bang Med J (Khulna) 2018; 51 : 40-43
- Published
- 2019
28. Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors
- Author
-
Kazushige Kawai, Masaya Hiyoshi, Koji Murono, Keisuke Hata, Manabu Kaneko, Hiroaki Nozawa, Kazuhito Sasaki, Toshiaki Tanaka, Hirofumi Sonoda, Yasutaka Shuno, Takeshi Nishikawa, and Shigenobu Emoto
- Subjects
Risk ,Oncology ,medicine.medical_specialty ,Receptor, Platelet-Derived Growth Factor alpha ,Time Factors ,Stromal cell ,Gastrointestinal Stromal Tumors ,medicine.medical_treatment ,Anal Canal ,Rectum ,Antineoplastic Agents ,Imatinib therapy ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,medicine ,Humans ,Stromal tumor ,neoplasms ,Digestive System Surgical Procedures ,Neoadjuvant therapy ,GiST ,Rectal Neoplasms ,business.industry ,Imatinib ,General Medicine ,Neoadjuvant Therapy ,digestive system diseases ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Mutation ,Imatinib Mesylate ,030211 gastroenterology & hepatology ,Surgery ,Neoplasm Recurrence, Local ,business ,Organ Sparing Treatments ,medicine.drug - Abstract
Rectal gastrointestinal stromal tumor (GIST) is a rare entity. Thus, its clinical features have not been well documented, and optimal treatment strategies have not been established. Surgery for rectal GISTs may be difficult because they are often large in size. In addition, rectal GISTs were found to be associated with high rates of local recurrence, regardless of the surgical procedure, before imatinib was introduced in the early 2000s. Since the introduction of imatinib therapy, accumulating evidence suggests that neoadjuvant imatinib therapy may improve the outcomes of rectal GIST treatment. Neoadjuvant imatinib therapy for rectal GISTs offers a number of potential benefits, including tumor downsizing, reduction in mitotic activity, reduced morbidity, and a reduced risk of recurrence. Less radical procedures may allow for the preservation of the anal sphincter and avoidance of a permanent colostomy. This review summarizes the current status and future perspectives of neoadjuvant imatinib therapy for the treatment of rectal GISTs.
- Published
- 2018
29. Diuretic-Resistant Ascites Following Laparoscopic Surgery in a Patient With Chronic Myeloid Leukemia on Imatinib Therapy
- Author
-
Pagona Gourna, Marina Gkeka, Efthymia Pappa, Ifigeneia Kiki, and Constantinos Christopoulos
- Subjects
imatinib therapy ,medicine.medical_specialty ,medicine.drug_class ,030204 cardiovascular system & hematology ,Gastroenterology ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,0302 clinical medicine ,chronic myeloid leukemia ,Internal medicine ,hemic and lymphatic diseases ,Ascites ,medicine ,Paracentesis ,Internal Medicine ,neoplasms ,diuretic-resistant ascites ,biology ,medicine.diagnostic_test ,business.industry ,General Engineering ,Myeloid leukemia ,Imatinib ,Hematology ,laparoscopic surgery ,Imatinib mesylate ,General Surgery ,biology.protein ,medicine.symptom ,business ,Tyrosine kinase ,030217 neurology & neurosurgery ,Platelet-derived growth factor receptor ,medicine.drug - Abstract
Imatinib mesylate is a tyrosine kinase inhibitor with high efficacy in the treatment of chronic myeloid leukemia (CML). Although fluid retention is a common adverse effect of imatinib, it rarely necessitates discontinuation of therapy. Isolated ascites has not been reported as a complication of imatinib therapy in patients with CML. Here, we report the case of a 72-year-old male with CML on imatinib (600 mg daily), who developed ascites two weeks after a laparoscopic hernia repair with intraperitoneal placement of a nylon mesh. The ascites was resistant to diuretic therapy and required repeated large-volume paracentesis. Discontinuation of imatinib resulted in arrest of ascites production, but reintroduction of the drug at the same dose two weeks later was rapidly followed by recurrence of ascites requiring further therapeutic paracenteses. It was postulated that peritoneal inflammation had resulted in increased capillary permeability, which was further augmented by imatinib via inhibition of platelet-derived growth factor receptor (PDGFR), a tyrosine kinase known to play a significant physiological role in the regulation of interstitial fluid pressure and capillary permeability. The possibility of developing ascites after abdominal surgery should be considered in patients receiving imatinib or related PDGFR inhibitors. In such cases, perioperative interruption of tyrosine kinase therapy might be indicated.
- Published
- 2021
30. Successful determination of imatinib dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction
- Author
-
Ryota Tanaka, Takahiro Sumimoto, Ryosuke Nakahara, Masao Ogata, and Hiroki Itoh
- Subjects
Oncology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Myeloid leukemia ,Imatinib ,Imatinib therapy ,Impaired renal function ,Therapeutic drug monitoring ,hemic and lymphatic diseases ,Internal medicine ,medicine ,In patient ,business ,neoplasms ,Dialysis ,medicine.drug - Abstract
Imatinib is used as first-line treatment for chronic myeloid leukemia (CML) even in patients with impaired renal function. We successfully used therapeutic drug monitoring to determine the dose for re-administration of imatinib in a CML patient who initiated dialysis for acute renal dysfunction associated with the initial imatinib therapy.
- Published
- 2021
31. Skuteczne odstawienie nilotynibu po niepowodzeniu terapii imatynibem
- Author
-
Tomasz Sacha and Joanna Wącław
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Hematology ,Imatinib therapy ,medicine.disease ,Therapeutic goal ,Discontinuation ,Nilotinib ,hemic and lymphatic diseases ,Internal medicine ,Molecular Response ,medicine ,Hematologist ,business ,Tyrosine kinase ,Chronic myelogenous leukemia ,medicine.drug - Abstract
Successful treatment of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKI) is nowadays likely to result in near-normal life expectancy. Nowadays, the treatment-free remission (TFR) is becoming more and more often a therapeutic goal for both hematologist and his patient. TKI discontinuation and maintenance of TFR is feasible in circa 40–50% of CML patients who achieved stable deep molecular response (DMR). Here, we present a patient with CML, who was switched to nilotinib due to imatinib therapy failure. After a few years of sustaining DMR nilotinib was discontinued. One year since this decision, the patient has remained in the TFR.
- Published
- 2021
32. COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy
- Author
-
M. Ruhul Quddus, Samuel L. Grindstaff, and Paul DiSilvestro
- Subjects
PDGFB ,Uterine sarcoma ,business.industry ,Obstetrics and Gynecology ,Imatinib therapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,lcsh:Gynecology and obstetrics ,lcsh:RC254-282 ,Oncology ,Correspondence ,Cancer research ,Medicine ,business ,lcsh:RG1-991 - Published
- 2020
33. CHRONIC MYELOID LEUKEMIA COURSE IN PERSONS EXPOSED TO IONIZING RADIATION AS A RESULT OF THE CHORNOBYL ACCIDENT
- Author
-
V. G. Fedorenko, A O Tovstogan, Z V Stupakova, I. V. Dmytrenko, Zh. M. Minchenko, O O Petrusha, Yu O Silayev, Z V Martina, T Yu Shlyakhtichenko, V. V. Sholoiko, and Iryna Dyagil
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Chromosomes, Human, Pair 22 ,Fusion Proteins, bcr-abl ,Gene Expression ,Bone Marrow Cells ,Imatinib therapy ,Disease ,Translocation, Genetic ,Ionizing radiation ,hemic and lymphatic diseases ,Internal medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Radiation, Ionizing ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Soil Pollutants, Radioactive ,Radiology, Nuclear Medicine and imaging ,Complete Cytogenetic Response ,In patient ,Radiation Injuries ,Food Contamination, Radioactive ,Aged ,business.industry ,Exogenous factor ,Emergency Responders ,Myeloid leukemia ,Middle Aged ,Radiation Exposure ,Prognosis ,Survival Analysis ,Radiation exposure ,Chernobyl Nuclear Accident ,Air Pollutants, Radioactive ,Drug Resistance, Neoplasm ,Imatinib Mesylate ,Female ,business ,Chromosomes, Human, Pair 9 ,Ukraine - Abstract
Describe and characterize the peculiarities of the chronic myeloid leukemia (CML) course and responseto treatment in patients irradiated as a result of the Chornobyl nuclear power plant (ChNPP) accident based on theassessment of clinical-laboratory and clinical parameters.The CML patients (n = 33) exposed to ionizing radiation as a result of the ChNPP accidentwere enrolled. The comparison group consisted of CML patients (n = 725) with no history of radiation exposure. Allpatients were in the chronic phase of the disease. Clinical, hematological and molecular genetic research methodswere applied.Patients exposed to ionizing radiation as a result of the ChNPP accident had no differences in CML manifestation, as well as in classical genetic markers at the onset of the disease compared with patients with no historyof radiation exposure. Reduction of tumor clone on imatinib therapy was significantly less effective in the patientsexposed to ionizing radiation than in cases of no history of radiation exposure. Cases of primary resistance were statistically significantly prevalent in the ChNPP accident consequences clean-up workers while in the residents ofradiologically contaminated areas a statistically significant increase in probability of loss of complete cytogeneticresponse (development of secondary resistance) to imatinib therapy was found. An association was found betweenthe radiation exposure and probability of loss of complete cytogenetic response to imatinib therapy in this group ofpatients.The radiation exposure in the history even many years before the onset of CML is an unfavorable exogenous factor responsible for the development of resistance to imatinib therapy.Meta: nadaty kharakterystyku osoblyvostiam perebigu khronichnoï miieloïdnoï leĭkemiï (KhML) ta vidpovidi na likuvannia sered oprominenykh vnaslidok avariï na Chornobyl's'kiĭ atomniĭ elektrostantsiï (ChAES) patsiientiv na osnovi otsinky kliniko-laboratornykh ta klinichnykh parametriv.Materialy i metody. Obstezheno 33 osoby iz KhML, iaki zaznaly diï ionizuiuchogo vyprominiuvannia vnaslidok avariïna ChAES. Grupu porivniannia sklaly 725 patsiientiv iz KhML bez radiatsiĭnogo anamnezu. Usi patsiienty znakhodylysia vkhronichniĭ fazi zakhvoriuvannia. Vykorystovuvaly kliniko-gematologichni ta molekuliarno-genetychni metody doslidzhennia.Rezul'taty. Patsiienty, iaki zaznaly vplyvu radiatsiĭnogo vyprominiuvannia, ne vidriznialys' osoblyvostiamymanifestatsiï KhML, porivniano z patsiientamy bez radiatsiĭnogo anamnezu, prote dlia nykh vyznachalasia nyz'ka efektyvnist' do terapiï imatynibom. U grupi uchasnykiv likvidatsiï naslidkiv avariï na ChAES statystychno znachushche perevazhaly vypadky rozvytku pervynnoï rezystentnosti, porivniano z grupoiu zhyteliv radiatsiĭno zabrudnenykh terytoriĭ ta grupoiu porivniannia. Vyiavleno statystychno znachushche pidvyshchennia chastoty vtraty dosiagnutoï povnoï tsytogenetychnoï vidpovidi na terapiiu imatynibom u patsiientiv, iaki buly evakuĭovani abo prozhyvaly na radiatsiĭno kontaminovanykh terytoriiakh, porivniano z patsiientamy bez radiatsiĭnogo anamnezu. Vyznacheno asotsiatyvnyĭ zv’iazokmizh vplyvom radiatsiĭnogo faktoru ta virogidnistiu vtraty dosiagnutoï povnoï tsytogenetychnoï vidpovidi na terapiiu imatynibom v tsiĭ grupi patsiientiv.Vysnovky. Naiavnist' radiatsiĭnogo oprominennia v anamnezi navit' za bagato rokiv do debiutu KhML, ie nespryiatlyvym seredovyshchnym faktorom, iakyĭ obumovliuie rozvytok rezystentnosti do terapiï imatynibom.
- Published
- 2020
34. A liver metastasis 7 years after resection of a low-risk duodenal gastrointestinal stromal tumor
- Author
-
Atsuhiro Watanabe, Ryujiro Kajikawa, Ichiro Omori, Tadateru Takahashi, Masayuki Shishida, Ryotaro Kajiwara, Seiji Sadamoto, Masashi Inoue, Masahiro Ikeda, Kazuhiro Toyota, Kazuaki Miyamoto, and Hiroyuki Sawada
- Subjects
medicine.medical_specialty ,Stromal cell ,business.industry ,Internal medicine ,Recurrent disease ,medicine ,Imatinib therapy ,Stromal tumor ,business ,medicine.disease ,Gastroenterology ,Metastasis ,Resection - Abstract
Duodenal gastrointestinal stromal tumors (dGISTs) are rare, and a lack of consensus exists regarding their therapeutic management particularly for recurrent disease. We present even low-risk dGIST may metastasize and require long-term observation, and a long-term prognosis may be achieved by combining resection and imatinib therapy for liver metastases recurrence.
- Published
- 2020
35. Lichen planopilaris related to imatinib therapy with good response to oral doxycycline
- Author
-
José Luis Rodríguez Peralto, Cristina Vico Alonso, Virginia Velasco Tamariz, Pablo Luis Ortiz Romero, Fátima Tous Romero, Raquel Aragón Miguel, Belén Pinilla Martínez, and Alba Calleja Algarra
- Subjects
Doxycycline ,medicine.medical_specialty ,business.industry ,medicine.drug_class ,Lichen Planus ,Dermatology ,General Medicine ,Imatinib therapy ,Lichen planopilaris ,Tyrosine-kinase inhibitor ,Imatinib Mesylate ,medicine ,Humans ,business ,medicine.drug - Published
- 2020
36. Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm
- Author
-
Sylvain Chantepie, Thomas Hueso, Alexandra Henry, Matthieu Decamp, Sarah Mensi, Hyacinthe Johnson-Ansah, Elsa Maitre, Gandhi Damaj, Jean-Pierre Vilque, Université de Caen Normandie (UNICAEN), Normandie Université (NU), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Génétique [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Biologie, génétique et thérapies ostéoarticulaires et respiratoires (BIOTARGEN), Normandie Université (NU)-Normandie Université (NU), Université de Caen Normandie - UFR Santé (UNICAEN Santé), Université de Reims Champagne-Ardenne (URCA), Institut d'Hématologie de Basse-Normandie (IHBN), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), and UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER
- Subjects
Oncology ,Bridge to transplant ,medicine.medical_specialty ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,business.industry ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,General Medicine ,Imatinib therapy ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,business ,Myeloproliferative neoplasm ,ComputingMilieux_MISCELLANEOUS ,030215 immunology - Abstract
International audience; No abstract available
- Published
- 2019
37. Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study
- Author
-
Pavel Žák, Petra Bělohlávková, Lukáš Semerád, Jiří Mayer, Zdeněk Ráčil, Edgar Faber, Lukas Stejskal, Jiřina Procházková, Zuzana Šustková, Daniela Žáčková, Tomáš Horňák, Peter Rohoň, and Barbora Weinbergerova
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Blood lipids ,Imatinib ,Hematology ,Imatinib therapy ,Statin treatment ,respiratory tract diseases ,3. Good health ,03 medical and health sciences ,0302 clinical medicine ,Nilotinib ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Prospective cohort study ,business ,Tyrosine kinase ,030215 immunology ,medicine.drug - Abstract
Tyrosine kinase inhibitors (TKI) have dramatically improved the prognosis of CML patients with life expectancy close to individuals without CML [1], and therefore the longterm safety of TKIs has become especially important due to the potential for lifelong treatment. Nilotinib (NILO) tends to have a negative effect on lipid [2] and glucose [3] metabolism, while imatinib (IMA) seems to improve [4] these abnormalities. Although the data appear convincing, the real impact of these changes on cardiovascular (CV) risk and the development of CV complications during TKI therapy have not yet been confirmed.
- Published
- 2019
38. Comparison of the applicability of Hasford score and European Treatment and Outcome Study score in Indian patients with chronic phase chronic myeloid leukemia on imatinib therapy
- Author
-
Mrinalini Kotru, Neha Chopra Narang, Usha Rusia, and Meera Sikka
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Imatinib therapy ,Hasford Score ,030204 cardiovascular system & hematology ,Chronic phase chronic myeloid leukemia ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 ,Outcome (game theory) ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,Oncology ,Internal medicine ,Physical therapy ,Medicine ,business ,Letter to the Editor ,030215 immunology - Published
- 2017
39. Laparoscopic Total Pelvic Exenteration After Neoadjuvant Imatinib Therapy for Gastrointestinal Stromal Tumor of the Rectum: A Case Report
- Author
-
Takashi Akiyoshi, Satoshi Nagayama, Yoshiya Fujimoto, Tsuyoshi Konishi, Toshiya Nagasaki, Masashi Ueno, Toshiharu Yamaguchi, and Yosuke Fukunaga
- Subjects
medicine.medical_specialty ,Pelvic exenteration ,GiST ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Locally advanced ,Rectum ,Imatinib therapy ,Pelvic wall ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine ,030211 gastroenterology & hepatology ,Stromal tumor ,business ,Laparoscopy ,neoplasms - Abstract
Total pelvic exenteration (TPE) may be the only curative procedure for locally advanced rectal gastrointestinal stromal tumor (GIST) that is contiguous with the adjacent organs and pelvic wall. There is no previous report of laparoscopic TPE for advanced rectal GIST. Here, we describe our experience of performing laparoscopic TPE on a locally advanced rectal GIST after neoadjuvant imatinib chemotherapy. A 62-year-old Japanese man was diagnosed with locally advanced rectal GIST that was contiguous with the seminal vesicles, prostate, and left pelvic sidewall. He received imatinib mesylate for 5 months, after which the mass had shrunk but was still contiguous with adjacent organs. We therefore needed to perform TPE, and we accomplished the operation laparoscopically. The total operative time was 540 minutes and estimated blood loss was 280 mL. There were no intraoperative complications and not required conversion to open surgery. The patient had his first stool on the first postoperative day and discharged on the 21st postoperative day with no major complication. Pathologic examination of the resected specimen revealed negative margins. The patient had further adjuvant imatinib chemotherapy and had no recurrence for 20 months postoperatively. Laparoscopic TPE appears to be minimally invasive surgery and safe in the present case of rectal GIST. This is the first report of a case in the world that underwent laparoscopic TPE for advanced rectal GIST.
- Published
- 2017
40. Variation in Adherence Measures to Imatinib Therapy
- Author
-
Pooja Chauhan, Deepesh Lad, Jasmeen Gill, Neha Saini, Gaurav Prakash, Kavita Sahu, Alka Khadwal, Deepika Rikhi, Uday Yanamandra, Neelam Varma, Subhash Varma, Savita Kumari, Vikas Suri, Pankaj Malhotra, and Yanamandra Sushma
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Epidemiology ,medicine.drug_class ,Decision Making ,MEDLINE ,India ,Antineoplastic Agents ,Imatinib therapy ,030204 cardiovascular system & hematology ,lcsh:RC254-282 ,Tyrosine-kinase inhibitor ,Medication Adherence ,Tertiary Care Centers ,03 medical and health sciences ,Myelogenous ,0302 clinical medicine ,Patient Education as Topic ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Surveys and Questionnaires ,Internal medicine ,medicine ,Humans ,Protein Kinase Inhibitors ,Cost of Cancer Care ,Population and observational studies (SEER, WHI observational, etc.) ,ABL ,business.industry ,Myeloid leukemia ,Health Services and Outcomes ,ORIGINAL REPORTS ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Leukemia ,Behavioral and Lifestyle Risk Factors ,Oncology ,030220 oncology & carcinogenesis ,Imatinib Mesylate ,Quality of Life ,Physical therapy ,Female ,Observational study ,business - Abstract
Purpose The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studied adherence from resource-constrained settings and tried to analyze the factors responsible for nonadherence in these individuals. We also correlated adherence to current molecular status. Patients and Methods This was a single-center, cross-sectional, observational study from north India. It consisted of a questionnaire-based survey in which a one-to-one interview technique was used by trained nursing staff administering the Modified Morisky Adherence Scale (MMAS-9) questionnaire. Adherence was also measured on the basis of physician’s assessment. JMP 13.0.0 was used for statistical analysis. Results A total of 333 patients with a median age of 42 years were included in the study. The median BCR-ABL/ABL ratio (IS) was 0.175 (0.0 to 98.0). The mean MMAS-9 score was 11 ± 2. Adherence was seen in 54.95% on the basis of MMAS-9, whereas physician’s assessment reported adherence in 90.39% of patients. Using the χ2 test, no relationship was found between the two assessment techniques. There was a significant relationship between major molecular response status and adherence by physician’s assessment and MMAS-9 ( P < .001). Bivariate analysis by logistic fit showed a good relation between the MMAS-9 score and the BCR-ABL/ABL ratio (IS), χ2 (1,220) = 135.45 ( P < .001). On multivariate analysis, enrolment in the Novartis Oncology Access program (a patient assistance program) was significantly associated with adherence ( P = .012). Conclusion This study highlights the lack of adherence in real-world settings and the various factors responsible. Such studies are important from a public health services perspective in various settings around the world because they may lead to corrective action being taken at the institutional level.
- Published
- 2017
41. Optimal response to imatinib therapy in a case of chronic myeloid leukemia with a concurrent loss of distal 22q
- Author
-
Fatma Saeed AlQahtani, Bayan S. Al-Qahtany, Abdurahman Almaeen, Aamer Aleem, and Osamah Khojah
- Subjects
Oncology ,medicine.medical_specialty ,Numerical Chromosomal Abnormality ,Treatment response ,lcsh:Diseases of the circulatory (Cardiovascular) system ,Imatinib therapy ,Disease ,Philadelphia chromosome ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,hemic and lymphatic diseases ,Medicine ,business.industry ,Myeloid leukemia ,Chromosome ,Hematology ,medicine.disease ,chronic myelogenous leukemia ,lcsh:RC666-701 ,030220 oncology & carcinogenesis ,Additional chromosomal abnormality ,business ,030215 immunology ,Chronic myelogenous leukemia - Abstract
The hallmark of diagnosing classical chronic myelogenous leukemia (CML) is the identification of Philadelphia (Ph) chromosome (Chr). However, some CML cases show additional structural/numerical chromosomal abnormalities involving either Ph Chr or more frequently other Chrs. Genetic alterations sparing Ph Chr are commonly called “additional chromosomal abnormalities (ACAs)” which have been extensively analyzed in recent large studies. In contrast, the presence of additional genetic abnormalities in Ph Chr has been anecdotally reported with an ambiguity of their impact on treatment response. In our case, we report a newly diagnosed CML patient with the rarest additional chromosomal aberration affecting Ph Chr which has revealed an optimal response over a period of 2 years of follow-up. This report underlines the importance of re-examining CML cases for any ACAs, especially those occurring in Ph Chr, which might be overlooked easily. Moreover, their possible role in disease prognostication should be sought, as well.
- Published
- 2017
42. The Neoadjuvant Imatinib Therapy Allowing for the Curative Resection of an Unresectable Duodenum GIST: A Case Report
- Author
-
Soichiro Morinaga, Yosuke Atsumi, Manabu Shiozawa, Koichiro Yamaoku, Masaaki Murakawa, Toru Aoyama, Takaki Yoshikawa, Tetsuta Satoyoshi, Keisuke Kazama, and Manabu Morimoto
- Subjects
Curative resection ,medicine.medical_specialty ,GiST ,business.industry ,Imatinib therapy ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine ,Duodenum ,030212 general & internal medicine ,business - Published
- 2017
43. Imatinib-induced Gastrointestinal Vascular Ectasia in a Patient with Advanced GIST: Case Report and Literature Review
- Author
-
Gil Bar-Sela, Mahmoud Abu-Amna, and Halim Awadie
- Subjects
Cancer Research ,medicine.medical_specialty ,Gastrointestinal Stromal Tumors ,Anemia ,Antineoplastic Agents ,Imatinib therapy ,Multimodal Imaging ,Gastroenterology ,Imatinib treatment ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,Ectasia ,medicine ,Humans ,neoplasms ,Aged ,GiST ,business.industry ,Gastric antral vascular ectasia ,Imatinib ,General Medicine ,medicine.disease ,Surgery ,Oncology ,Positron-Emission Tomography ,030220 oncology & carcinogenesis ,Imatinib Mesylate ,Female ,030211 gastroenterology & hepatology ,Upper gastrointestinal bleeding ,Tomography, X-Ray Computed ,business ,Gastric Antral Vascular Ectasia ,medicine.drug - Abstract
BACKGROUND Imatinib is generally well tolerated in the treatment of advanced gastrointestinal stromal tumors (GIST). Gastrointestinal vascular ectasia (GIVE) and gastric antral vascular ectasia (GAVE), while rare, are significant under-reported complications of imatinib therapy. CASE REPORT We present one patient with GIVE complicating imatinib therapy with a literature review of this rare side-effect. RESULTS A 68-year-old woman was diagnosed with advanced GIST, wild-type CKIT. After 3 months of treatment with imatinib, she had partial response. However, she was diagnosed with GAVE and, later, also with GIVE. During her 3-year imatinib treatment, she suffered from severe anemia and required blood transfusions. Conservative treatments were not helpful and the ectatic lesions resolved only with cessation of imatinib. CONCLUSION This confirms a causal relationship between GIVE and imatinib. GIVE and GAVE should be considered possible causes of anemia and upper gastrointestinal bleeding in patients receiving imatinib therapy.
- Published
- 2016
44. Pemphigus foliaceus associated with imatinib therapy in a patient with gastrointestinal stromal tumor
- Author
-
Wen-Shan Chen, Chi-Shun Yang, Yi-Ju Chen, and Chao-Kuei Juan
- Subjects
business.industry ,Dermatology ,Imatinib therapy ,medicine.disease ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Pemphigus ,0302 clinical medicine ,Imatinib mesylate ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,Stromal tumor ,business ,Pemphigus foliaceus - Published
- 2018
45. The effects of time valuation in cancer optimal therapies: a study of chronic myeloid leukemia
- Author
-
Julia Martínez-Rodríguez, M. A. López-Marcos, Jose Russo, and Pedro José Gutiérrez-Diez
- Subjects
Time valuation factor ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Drug doses ,Time Factors ,Systems biology ,030231 tropical medicine ,Health Informatics ,Cell Communication ,Disease ,lcsh:Computer applications to medicine. Medical informatics ,Malignancy ,Models, Biological ,03 medical and health sciences ,System of difference equations ,0302 clinical medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Internal medicine ,medicine ,Humans ,Optimal control problem ,lcsh:QH301-705.5 ,Biomedicine ,Valuation (finance) ,business.industry ,Research ,Chronic myeloid leukemia ,Myeloid leukemia ,Imatinib therapy ,medicine.disease ,Hematopoiesis ,030104 developmental biology ,lcsh:Biology (General) ,Modeling and Simulation ,Calibration ,Cancer cell ,lcsh:R858-859.7 ,business - Abstract
Background The mathematical design of optimal therapies to fight cancer is an important research field in today’s Biomathematics and Biomedicine given its relevance to formulate patient-specific treatments. Until now, however, cancer optimal therapies have considered that malignancy exclusively depends on the drug concentration and the number of cancer cells, ignoring that the faster the cancer grows the worse the cancer is, and that early drug doses are more prejudicial. Here, we analyze how optimal therapies are affected when the time evolution of treated cancer is envisaged as an additional element determining malignancy, analyzing in detail the implications for imatinib-treated Chronic Myeloid Leukemia. Methods Taking as reference a mathematical model describing Chronic Myeloid Leukemia dynamics, we design an optimal therapy problem by modifying the usual malignancy objective function, unaware of any temporal dimension of cancer malignance. In particular, we introduce a time valuation factor capturing the increase of malignancy associated to the quick development of the disease and the persistent negative effects of initial drug doses. After assigning values to the parameters involved, we solve and simulate the model with and without the new time valuation factor, comparing the results for the drug doses and the evolution of the disease. Results Our computational simulations unequivocally show that the consideration of a time valuation factor capturing the higher malignancy associated with early growth of cancer and drug administration allows more efficient therapies to be designed. More specifically, when this time valuation factor is incorporated into the objective function, the optimal drug doses are lower, and do not involve medically relevant increases in the number of cancer cells or in the disease duration. Conclusions In the light of our simulations and as biomedical evidence strongly suggests, the existence of a time valuation factor affecting malignancy in treated cancer cannot be ignored when designing cancer optimal therapies. Indeed, the consideration of a time valuation factor modulating malignancy results in significant gains of efficiency in the optimal therapy with relevant implications from the biomedical perspective, specially when designing patient-specific treatments., This work was supported by projects MTM2014-56022-C2-2-P and MTM2017-85476-C2-1-P of the Spanish Office of Innovation and Competitiveness and European FEDER Funds, and by projects of the Castile and León Autonomous Government: VA041P17 (with European FEDER Funds), VA138G18 and VA148G18.
- Published
- 2019
46. Gastrointestinal stromal tumours at Inkosi Albert Luthuli Central Hospital from 2005 to 2015
- Author
-
Frank Anderson, Solomon N. Mutua, Kalpesh G. Mody, and Nozipho E. Nyakale
- Subjects
imatinib therapy ,medicine.medical_specialty ,GiST ,business.industry ,Stomach ,Inkosi Albert Luthuli Central ,Imatinib ,Disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Malignancy ,medicine.disease ,lcsh:RC254-282 ,gastrointestinal stromal tumors ,Stable Disease ,medicine.anatomical_structure ,Internal medicine ,medicine ,Population study ,business ,Adverse effect ,neoplasms ,medicine.drug - Abstract
Background: Gastrointestinal stromal tumour (GIST) is the commonest mesenchymal malignancy of the gastrointestinal tract. Patient demographics and outcomes following imatinib therapy in South Africa are unknown. Aim: To establish the patient demographics of GIST and the clinical outcomes following imatinib therapy. Setting: Inkosi Albert Luthuli Central Hospital (IALCH), Durban, South Africa. Methods: A quantitative, retrospective, descriptive chart review study was conducted. The study population included patients with a histologic diagnosis of GIST who presented between January 2005 and December 2015 to the facility. Only patients who received imatinib were included in the clinical outcome analysis. Results: Sixty-nine patients were seen during the study period. The mean (SD) age at diagnosis was 57.3 (13.5) years. The male gender (53.6%) was predominant, the black ethnic group (53.6%) was the commonest and the stomach (69.6%) was the most common disease site. Localised disease (53.6%) was the commonest disease category, while high risk (29.7%) and intermediate risk (29.7%) were the majority risk categories. Thirty-six (52.2%) patients received imatinib with a median (IQR) follow-up time of 20.5 (38) months. Eighty-one per cent of patients with localised disease remained in remission after adjuvant imatinib, and 18.2% developed metastatic recurrence. Among patients with locally advanced disease, 81.8% attained partial response on neoadjuvant imatinib, while 9.1% had stable disease. Most (75%) patients with metastatic disease attained partial response as the best response to imatinib. The most common adverse effects were anaemia and fluid overload. Conclusion: At IALCH, GIST is more common in the male gender, black ethnic group and in the stomach. The majority of localised and locally advanced GIST patients have favourable outcomes on imatinib. However, most metastatic GIST patients eventually develop resistance to imatinib necessitating further treatment options.
- Published
- 2019
47. Flow Cytometric Analysis of T Lymphocyte Activation in CML Patients Under Imatinib Therapy
- Author
-
Onder Arslan, Mutlu Arat, Muhit Ozcan, Klara Dalva, Deniz Goren Sahin, Sema Meric, and Gunhan Gurman
- Subjects
Gynecology ,chronic myelogenous leukemia,flow cytometry,imatinib,T cell ,medicine.medical_specialty ,kronik miyelositer lösemi,akım sitometri,imatinib,T hücre ,business.industry ,Health Care Sciences and Services ,medicine ,Imatinib therapy ,Sağlık Bilimleri ve Hizmetleri ,business ,T-lymphocyte activation - Abstract
İmatinibin in vivo ortamda T lenfositfonksiyonları üzerine olan etkileri akım sitometrik olarakdeğerlendirilmiştir. Çalışmaya toplam 29 KML hastası ve 9 sağlıklı bireydahil edilmiştir. KML hastaları kendi aralarında sırasıyla, yeni tanı almış vetedavi görmeyen, 1 yıldır imatinib alan ve 1 yıldan uzun süredir imatinib alanhastalar olarak 3 gruba ayrılmıştır. CD4+ hücreler ve bu hücrelerdeki IL-4ve IFNg ifadeleri, CD3+ T lenfositlerin % kaçının aktive edilmiş olduğu(CD3+CD69+), CD8+ hücreler ve bu hücrelerde HLA-ABC ve HLA-DR ifade edenhücrelerin oranı ve HLA-ABC ve HLA-DR ifadelerinin şiddeti değerlendirilmiştir. Gruplar arasında ortalama CD4 + hücresayısı açısından anlamlı fark yoktu. Bununla birlikte, kontrol grubunda dahayüksek CD4 + hücrelerine doğru bir eğilim vardı. IL-4 ve IFN gama, gruplararasında istatistiksel olarak anlamlı bulunmadı. Kontrol grubu daha düşük IL-4ve IFN gama ifade değerlerine sahipti. IL-4 ve IFN gama ifade etmeyen ortalamaCD4 + hücre sayısı kontrol grubunda diğer gruplara göre istatistiksel olarakdaha yüksekti. Kontrol grubunda ise % aktivasyon diğer gruplara göre azdı. Tümhasta gruplarında CD8 + hücre oranı istatistiksel olarak daha düşük bulundu (p= 0,001). HLA-ABC ve HLA-DR'nin CD8 + hücrelerinde ekspresyonu gruplar arasındabenzerdi. İmatinibin sitokin sentezi üzerine herhangi bir etkisigözlenmemiştir. İmatinib tedavisi altındaki hastalarda T lenfositfonksiyonlarının etkilendiğine dair klinik belirgin gözlemler olmamaklabirlikte, subklinik etki varlığı araştırma konusudur. Yapılan in vitro çalışmaların in-vivokorele olup olmadığının aydınlatılabilmesi için daha ileri çalışmalaragereksinim vardır., To analyzeT cell functions by flow cytometry and to evaluate the possible functionalchanges that might occur under imatinib therapy in CML patients. A total of 29patients and 9 healthy control subjects were enrolled. Newly diagnosed patientshaving no treatment (group 1), patients receiving imatinib for 1 year (group 2)and patients receiving imatinib more than 1 year (group 3), healthy controlsubjects (group 4). IL-4 and IFN gamma expression on CD4+ cells; how muchpercentage of CD3+ T cells were activated (CD3+CD69+); CD8+ T cells and theratio and grade of expression of HLA-ABC and HLA-DR on those cells wereevaluated, respectively. There wasno significant difference in terms of mean number of CD4+ cells between thegroups. However, there was a tendency towards higher CD4+ cells in controlgroup. IL-4 and IFN gamma were found not to be statistically significantbetween the groups. Control group has lower IL-4 and IFN gamma expressionvalues. Mean number of CD4+ cells, which did not express IL-4 and IFN gamma,were statistically higher in control group when compared to other groups. Incontrol group, % activation was decreased when compared to that of othergroups. CD8+ cell ratio was found to be statistically lower in all patientgroups (p=0.001). The expression of HLA-ABC and HLA-DR on CD8+ cells weresimilar between the groups. We could not show any inhibitory effect of imatinibon T cell functions in concordance with clinical experience and safety profile.
- Published
- 2019
48. A Case of Repeat Urgent Surgery Hemoperitoneum due to Ruptured Peritoneal Dissemination of Gastric GIST during Imatinib Therapy
- Author
-
Haruki Mori, Yuichi Takayama, Shunsuke Onoe, Yuji Kaneoka, Yasuyuki Fukami, and Atsuyuki Maeda
- Subjects
medicine.medical_specialty ,business.industry ,General surgery ,Imatinib therapy ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,030211 gastroenterology & hepatology ,Hemoperitoneum ,medicine.symptom ,business ,Gastric GIST - Published
- 2016
49. A case of severe digital vasculopathy during imatinib therapy in a hemodialysis patient with chronic myeloid leukemia
- Author
-
Sachiyo Osawa, Yoshihiro Takami, Takashi Naito, Kosaku Nitta, Hayato Mikami, Kotoko Yamatani, Tetsuya Yoshikura, and Kazuho Honda
- Subjects
Oncology ,medicine.medical_specialty ,Computer Networks and Communications ,business.industry ,medicine.medical_treatment ,Myeloid leukemia ,Imatinib therapy ,03 medical and health sciences ,0302 clinical medicine ,Hardware and Architecture ,030220 oncology & carcinogenesis ,Internal medicine ,Medicine ,Hemodialysis ,business ,Software ,030215 immunology - Published
- 2016
50. PRIMARY GASTROINTESTINAL STROMAL TUMOUR OF THE PROSTATE: A CASE REPORT OF A RARE TUMOUR
- Author
-
Nouman Khan, Azfar Ali, Khurram Mir, and Muhammad Arshad Irshad Khalil
- Subjects
medicine.medical_specialty ,Stromal cell ,business.industry ,Prostatectomy ,medicine.medical_treatment ,Urology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Imatinib therapy ,urologic and male genital diseases ,Bladder outlet obstruction ,medicine.anatomical_structure ,Prostate ,Medicine ,In patient ,business ,RC254-282 ,Enlarged prostate ,Antigen levels - Abstract
A 70-year-old gentleman underwent prostatectomy for bladder outlet obstruction due to enlarged prostate and was found to have primary extragastrointestinal stromal tumour (EGIST). He has been started on imatinib therapy and is presently on follow-up. Prostatic EGIST should be one of the differential diagnoses in patients with enlarged prostate with normal prostate-specific antigen levels.Key words: Prostate, gastrointestinal stromal tumour, PSA
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.